Radiomics and PD-L1 Expression Predict Immunotherapy Benefits in Patients with Head and Neck Squamous Cell Carcinoma

Overview

Journal Future Oncol

Specialty Oncology

Date 2024 Jun 11

PMID 38861311

Authors

Yongsik Sim

Beomseok Sohn

Sooyon Kim

Hye Ryun Kim

Min Hee Hong

Jinna Kim

Seung-Koo Lee

Sun Min Lim

Affiliations

Soon will be listed here.

Abstract

To evaluate the performance of MRI-derived radiomic risk score (RRS) and PD-L1 expression to predict overall survival (OS) and progression-free survival (PFS) of patients with recurrent head and neck squamous cell carcinoma receiving nivolumab therapy. Three hundred forty radiomic features from pretreatment MRI were used to construct the RRS. The integrated area under the receiver operating characteristic curve (iAUC) was calculated to evaluate the performance of the RRS and PD-L1. The RRS showed iAUCs of 0.69 and 0.57 for OS and PFS, respectively. PD-L1 expression showed iAUCs of 0.61 and 0.62 for OS and PFS, respectively. RRS and PD-L1 potentially predict the OS and PFS of patients with recurrent head and neck squamous cell carcinoma receiving nivolumab therapy.

References

Gibney G, Weiner L, Atkins M . Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016; 17(12):e542-e551. PMC: 5702534. DOI: 10.1016/S1470-2045(16)30406-5. View

Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

Mannil M, von Spiczak J, Manka R, Alkadhi H . Texture Analysis and Machine Learning for Detecting Myocardial Infarction in Noncontrast Low-Dose Computed Tomography: Unveiling the Invisible. Invest Radiol. 2018; 53(6):338-343. DOI: 10.1097/RLI.0000000000000448. View

Yuan Y, Ren J, Shi Y, Tao X . MRI-based radiomic signature as predictive marker for patients with head and neck squamous cell carcinoma. Eur J Radiol. 2019; 117:193-198. DOI: 10.1016/j.ejrad.2019.06.019. View

Zhang L, Dong D, Li H, Tian J, Ouyang F, Mo X . Development and validation of a magnetic resonance imaging-based model for the prediction of distant metastasis before initial treatment of nasopharyngeal carcinoma: A retrospective cohort study. EBioMedicine. 2019; 40:327-335. PMC: 6413336. DOI: 10.1016/j.ebiom.2019.01.013. View

Liu J, Mao Y, Li Z, Zhang D, Zhang Z, Hao S . Use of texture analysis based on contrast-enhanced MRI to predict treatment response to chemoradiotherapy in nasopharyngeal carcinoma. J Magn Reson Imaging. 2016; 44(2):445-55. DOI: 10.1002/jmri.25156. View

van Griethuysen J, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V . Computational Radiomics System to Decode the Radiographic Phenotype. Cancer Res. 2017; 77(21):e104-e107. PMC: 5672828. DOI: 10.1158/0008-5472.CAN-17-0339. View

Ren J, Tian J, Yuan Y, Dong D, Li X, Shi Y . Magnetic resonance imaging based radiomics signature for the preoperative discrimination of stage I-II and III-IV head and neck squamous cell carcinoma. Eur J Radiol. 2018; 106:1-6. DOI: 10.1016/j.ejrad.2018.07.002. View

Zhang L, Zhou H, Gu D, Tian J, Zhang B, Dong D . Radiomic Nomogram: Pretreatment Evaluation of Local Recurrence in Nasopharyngeal Carcinoma based on MR Imaging. J Cancer. 2019; 10(18):4217-4225. PMC: 6691694. DOI: 10.7150/jca.33345. View

10.

Mao J, Fang J, Duan X, Yang Z, Cao M, Zhang F . Predictive value of pretreatment MRI texture analysis in patients with primary nasopharyngeal carcinoma. Eur Radiol. 2019; 29(8):4105-4113. PMC: 6610272. DOI: 10.1007/s00330-018-5961-6. View

11.

Zhang B, Tian J, Dong D, Gu D, Dong Y, Zhang L . Radiomics Features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma. Clin Cancer Res. 2017; 23(15):4259-4269. DOI: 10.1158/1078-0432.CCR-16-2910. View

12.

Wang G, He L, Yuan C, Huang Y, Liu Z, Liang C . Pretreatment MR imaging radiomics signatures for response prediction to induction chemotherapy in patients with nasopharyngeal carcinoma. Eur J Radiol. 2017; 98:100-106. DOI: 10.1016/j.ejrad.2017.11.007. View

13.

Chouaib S, Noman M, Kosmatopoulos K, Curran M . Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene. 2016; 36(4):439-445. PMC: 5937267. DOI: 10.1038/onc.2016.225. View

14.

Fujima N, Shimizu Y, Yoshida D, Kano S, Mizumachi T, Homma A . Multiparametric Analysis of Tumor Morphological and Functional MR Parameters Potentially Predicts Local Failure in Pharynx Squamous Cell Carcinoma Patients. J Med Invest. 2021; 68(3.4):354-361. DOI: 10.2152/jmi.68.354. View

15.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

16.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

17.

Matoba T, Minohara K, Kawakita D, Takano G, Oguri K, Murashima A . Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors. Sci Rep. 2022; 12(1):14319. PMC: 9395325. DOI: 10.1038/s41598-022-18611-z. View

18.

Leijenaar R, Carvalho S, Hoebers F, Aerts H, van Elmpt W, Huang S . External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma. Acta Oncol. 2015; 54(9):1423-9. DOI: 10.3109/0284186X.2015.1061214. View

19.

McBride S, Sherman E, Tsai C, Baxi S, Aghalar J, Eng J . Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2020; 39(1):30-37. PMC: 8462641. DOI: 10.1200/JCO.20.00290. View

20.

van Dijk L, Thor M, Steenbakkers R, Apte A, Zhai T, Borra R . Parotid gland fat related Magnetic Resonance image biomarkers improve prediction of late radiation-induced xerostomia. Radiother Oncol. 2018; 128(3):459-466. PMC: 6625348. DOI: 10.1016/j.radonc.2018.06.012. View